Exenatide
- Generic Name
- Exenatide
- Brand Names
- Bydureon, Byetta
- Drug Type
- Biotech
- CAS Number
- 141758-74-9
- Unique Ingredient Identifier
- 9P1872D4OL
- Background
Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulations. Bydureon, the brand name product of extended-release exenatide in an injectable suspension, was discontinued in 2021. Bydureon BCise, an auto-injector extended-release formulation, remains available.
- Indication
Exenatide is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes. An extended-release formulation is available which is indicated in patients ≥10 years old, while the immediate-acting formulation is approved only for adult patients.
- Associated Conditions
- Type 2 Diabetes Mellitus
A Study to Assess the Effect of Exenatide Treatment on Mean 24-Hour Heart Rate in Patients With Type 2 Diabetes
- First Posted Date
- 2007-08-14
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT00516074
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of BMS-686117 in Subjects With Type 2 Diabetes
- First Posted Date
- 2007-07-27
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 36
- Registration Number
- NCT00508287
- Locations
- 🇺🇸
Elite Research Institute, Miami, Florida, United States
🇺🇸Orlando Clinical Research Center, Orlando, Florida, United States
🇺🇸New Orleans Center For Clinical Research, Knoxville, Tennessee, United States
A Pilot Study of Effects of Exenatide on Body Weight in Non-Diabetic, Obese Patients
- First Posted Date
- 2007-07-12
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 163
- Registration Number
- NCT00500370
- Locations
- 🇵🇷
Research Site, San Juan, Puerto Rico
A Study to Compare the Effects of Exenatide and Sitagliptin on Postprandial Glucose in Subjects With Type 2 Diabetes Mellitus
- First Posted Date
- 2007-05-23
- Last Posted Date
- 2015-08-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 102
- Registration Number
- NCT00477581
- Locations
- 🇺🇸
Research Site, San Antonio, Texas, United States
The Effect of Exenatide on Weight and Hunger in Obese, Healthy Women
- Conditions
- ObesityImpaired Glucose Tolerance
- Interventions
- Drug: Placebo
- First Posted Date
- 2007-04-05
- Last Posted Date
- 2017-09-11
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 41
- Registration Number
- NCT00456885
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Role of Exenatide in Type 1 Diabetes
- First Posted Date
- 2007-04-04
- Last Posted Date
- 2019-02-26
- Lead Sponsor
- Montefiore Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT00456300
- Locations
- 🇺🇸
Texas Children's Hospital/ Baylor College of Medicine, Houston, Texas, United States
Effect of Exenatide Plus Metformin vs. Insulin Aspart Plus Metformin on Glycemic Control and Hypoglycemia in Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: premixed insulin aspart twice daily (BID)
- First Posted Date
- 2007-02-14
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 494
- Registration Number
- NCT00434954
- Locations
- 🇩🇪
Research Site, Wolfsburg, Germany
A Study to Assess the Effect on Glucose Control and Safety and Tolerability of LY2148568 In Japanese Patients With Type 2 Diabetes
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-09-28
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 153
- Registration Number
- NCT00382239
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
Safety and Efficacy of Exenatide as Monotherapy
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2015-02-23
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 233
- Registration Number
- NCT00381342
- Locations
- 🇷🇺
Research Site, St. Petersburg, Russian Federation
Effect on Weight Loss of Exenatide Versus Placebo
- First Posted Date
- 2006-09-13
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 196
- Registration Number
- NCT00375492
- Locations
- 🇺🇸
Research Site, Renton, Washington, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.